EpiAxis
Prolonging remissionEpiAxis
Leading epigenetic company with a focus on the prevention of metastatic disease
Images
Blog Posts
20th October, 2023
EpiAxis confirms epiresatide as a first-in-class CoRest Complex Disruptor
EpiAxis Therapeutics (EpiAxis) is pleased to announce that newly completed research confirms its lea...
6th September, 2023
EpiAxis presents at Venture & Capital Singapore
EpiAxis CEO Dr Jeremy Chrisp recently presented at Wholesale Investor’s Venture and Capital 2023, an...
28th July, 2023
EpiAxis heads to Venture & Capital Sydney investor conference
EpiAxis Therapeutics is delighted to announce its participation in the Venture & Capital Sydney inve...
15th July, 2023
EpiAxis presents at Venture & Capital Europe Conference
EpiAxis Therapeutics was thrilled to present at the Wholesale Investor Venture & Capital Europe Conf...
22nd June, 2023
EpiAxis nominates EP-132.0 as lead candidate for IND advancement, renamed epiresatide
EpiAxis Therapeutics is pleased to announce the nomination of epiresatide as its lead candidate for ...
9th January, 2023
EpiAxis Therapeutics to present at Biotech Showcase 2023
EpiAxis Therapeutics, a leading LSD1 company with a focus on the treatment, diagnosis and monitoring...
7th November, 2022
EpiAxis enters agreement with Seattle Children’s Research Institute
EpiAxis Therapeutics has signed a material transfer agreement (MTA) with Seattle Children’s Research...
22nd October, 2022
EpiAxis joins Tech Tuesday panel discussion
EpiAxis Therapeutics CEO Dr Jeremy Chrisp this week joined Tech Tuesdays, a Canadian Securities Exch...
5th October, 2022
EpiAxis presents at BioPharm America 2022
EpiAxis Therapeutics recently presented at BioPharm America 2022, part of Biotech Week Boston, givin...
12th September, 2022
EpiAxis enters strategic partnership with UHN
EpiAxis Therapeutics and University Health Network (UHN) – Canada’s largest and leading research hos...